[Draft guideline regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine].

MLA

Kinuya, Seigo, et al. “[Draft Guideline Regarding Appropriate Use of 131I-MIBG Radiotherapy for Neuroendocrine Tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine].” Kaku Igaku. The Japanese Journal of Nuclear Medicine, vol. 52, no. 1, Feb. 2015, pp. 1–15. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=26502667&authtype=sso&custid=ns315887.

APA

Kinuya, S., Yoshinaga, K., Higuchi, T., Jinguji, M., Kawamoto, H., & Kurihara, H. (2015). [Draft guideline regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine]. Kaku Igaku. The Japanese Journal of Nuclear Medicine, 52(1), 1–15.

Chicago

Kinuya, Seigo, Keiichiro Yoshinaga, Tetsuya Higuchi, Megumi Jinguji, Hiroshi Kawamoto, and Hiroaki Kurihara. 2015. “[Draft Guideline Regarding Appropriate Use of 131I-MIBG Radiotherapy for Neuroendocrine Tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine].” Kaku Igaku. The Japanese Journal of Nuclear Medicine 52 (1): 1–15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=26502667&authtype=sso&custid=ns315887.